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T YPE IV glycogen storage disease is a rare autoso-
mal recessive disorder (also called Andersen's dis-
easel or amylopectinosis) in which the activity of 
branching enzyme alpha-I, 4-g1ucan: alpha-I, 4-g1u-
can 6-g1ucosyltransferase is deficient in the liver as 
well as in cultured skin fibroblasts and other tissues.2,3 
This branching enzyme is responsible for creating 
branch points in the normal glycogen molecule. In the 
relative or absolute absence of this enzyme, an insolu-
ble and irritating form of glycogen, an amylopectin-
like polysaccharide that resembles plant starch, accu-
mulates in the cells. The amylopectin-like form is less 
soluble than normal glycogen, with longer outer and 
mner chains and fewer branch points. The clinical 
onset of the disease is insidious, with nonspecific 
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gastrointestinal symptoms at first, followed by pro-
gressive hepatosplenomegaly, portal hypertension, as-
cites, and hepatic failure. Children with this disorder 
usually die of hepatic cirrhosis by the age of two 
to four years.4-8 In exceptional cases, cardiomyopa-
thy,5-7,9 neurologic syndromes - including tremors, 
seizures, and dementia1o,11 - or variable manifesta-
tions of myopathy5.12,13 have been reported. In pa-
tients with these unusual symptoms, the clinical onset 
is frequently later than in typical cases, and death 
most often results from cardiac failure. 
Liver transplantation for Type IV glycogen stora.ge 
disease was attempted in 1972; the recipient died 110 
days later after the rejection of the first liver trans-
plant and attempted retransplantation. 14 Liver trans-
plantation was first performed successfully in Septem-
ber 1984 in Patient 1 of this series; since that time we 
have treated six more such patients. Our experience 
with these seven patients forms the basis of this report. 
CASE REpORTS 
All the patients were boys. including- two sets of brothers (Table 
I). All had progressive liver failure with massIve hepatomegalv, 
splenome'Salv, and ascites. lBeca'use patients with Tvpe IV glyco· 
gen storage rlisease but without pro~ressive liver disease have occa-
sionallv been reported, i6 pro'5ressive liver disease was a condition 
for transplantation in each case.) Two of the seven patients died 
i Clnd 36 davs after liver transplantation - from a bowel perforation 
and thrombosis of the hep:ltic artery, respectively. The jive other 
recipients 171 percent) are healthy and have normal liver lunction 
16 (0 73 months after transpiantation. The five transplant recipIents 
who ,urvived were hospitalized for 26 to 49 days Imean. +0). The 
mean (=:SD) cost of transplantation in these five patients. including 
all professional lees, was ~ 107 ,900±30.000. Rehospitalization was 
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!lOt required except for follow-up !)ercuraneous needle biopsies of 
the :iVf:'i. peri()rrneci 1 TO +5 nlonths ~lfter cransplantJ.ticn, 1)1' :raLS-
jugular enJomvoc:udial biopsies. performed :3 weeks w 54 months 
atier transplantation (Table 2). The transplantations and tallow-up 
biopsies were undertaken with informed parental consent. The bi-
opsy procedures were considered essential for optimal care of the 
patients and were not part of a prospective experimentai design. 
Height. weight, gross and tine motor development. and language 
ability were retarded in all patients before transplantation. The 
physical strength and mOlor skills of tbe five survivors improved 
steadily alter transplantation. All have had a normal growth rate, 
two are performing well in elementary school, and the three in 
preschool have no apparent abnormalities in intellectual develop-
ment. None has had any cardiac symptoms or any evidence of 
abnormalities on chest films or electrocardiographic and echocar-
diographic examinations. A magnetic resonance imaging scan of 
the heart in one child was normal more than four years aftcr trans-
plantation. 
METHODS 
Liver Transplantation 
The diseased liver was totally excised and replaced with a size-
matched cadaveric liver, which was revascularized in an anatomi-
cally normal manner and provided biliary drainage with a Roux-
eu-Y choledochojej unostomv. 17 Immunosuppressive therapy con-
sisted of cyclosporine and prednisone. The daily maimcnance dose 
of prednisone in the five surviving patients was 5 mg or less. 
Tissue Studies 
Cultured skin fibroblasts and homogenates of liver tissue from 
the patients were assayed at Washington University for branching-
enzyme activity. The phosphorylase-coupled assay measured the 
rate of formation of inorganic phosphate from glucose-I-phosphate 
as glucose was polymerized to glycogen by the tissue homoge-
nates. J ,6,1S The branching-enzyme activity in skin fibroblasts aver-
aged 0.08 fLmol of inorganic phosphate per minute per milligram of 
protein, which was less than 10 percent of the activity in normal 
subjects (Table I). 
Amylopectin was sought on light-microscopical examination in 
the excised livers, in liver-biopsy samples obtained after transplan-
tation, and in other tissues obtained at the time of transplantation 
or at autopsy. The characteristic inclusions were positive on period-
ic acid-Schiff staining after digestion with diastase (PAS-D). Elec-
tron-microscopical studies demonstrated the fibrillar aggregations 
that are tvpical of amylopectin. '"-20 
Morphometric studies were performed on PAS-D-stained myo-
cardial tissue obtained at autopsy from one patient and endomyo-
cardial-biopsy samples from three others obtained at various times 
Table 1, Clinical Data on Patients with Type IV Glycogen Storage 
Disease Who Underwent Liver Transplantation. 
SK1N·FIBROBLAST 
PATIENT ,'\GE AT TRA.NS- BRANCHING-ENZYME DATE OF 
:KfoKD~ PLANTATION -\CTIYITyt OPERA nON 
,"0 jKgKmoflminfm~ 
31 0.10 916184 
II 0.07 ~1OU1Up 
36 0.11 915'85 
.. .)6 1).11 1l/2SIR5 
"" 
1),08 :0124187 
') ::0 0.06 jl21 i R9 
34 0.09 5/26189 
'PatH::nts I Jnci tJ were brothers. as were Patients J and 5. 
LENGTH Of 
SURVIVAL 
73 rno 
Died 7 days after 
transplantation 
Died 36 days aiter 
"ansplantation 
58 rna 
35 rna 
:8 rna 
:6 rno 
"Norma! branching-enzyme activity in skin fibroblasts. i to 2 ~mog per minute per millIgram 
It protem. ;.15 
table 2. Deposits Positive on Periodic Acid-Schiff Staining after 
Digestion with Diastase (PAS-C) in the Myocardium of Four Pa-
tients with Type IV Glycogen Storage Disease after Liver 
Transplantation. 
PA TlENT 
No. 
7 
TIME AFTER 
TRANSPLAN-
T ATION 
rno 
54.0 
1.2 
(at autopsy) 
0.9 
14.0 
1.0 
11.0 
No. OF INCLUSIONS 
per 3.6xJ05 jJ.l112 
24 
46 
332 
129 
Too few to quantitate 
Too few to quantitate 
MEAN AREA MEAN SIZE 
OCCUPIED BY OF INCLU-
INCLUSIONS SIONS 
% IJ • .m 2 
05 140 
2 141 
13 146 
5.9 164 
after transplantation (Table 2). with the Bioquant System IV 
(R&M Biometrics. Nashville) used for automated image analysis. 
Tbe biopsy samples were also separately evaluated with the point-
count technique. To eliminate artifacts caused by vessel" or com-
pression, interstitial and vascular spaces in the field were eliminated 
from the final calculations of the area of amylopectin deposition. 
Variation within samples was studied in 24 tields rrn~ a large piece 
of left ventricle obtained at autopsy from Patient 3. All the fields 
had much the same amylopectin distribution, with the single excep-
tion of a superficial subendocardial field that contained little 
muscle. 
RESULTS 
There was no trace of amylopectin in the graft of 
the child who died 36 days after transplantation from 
hepatic-artery thrombosis or in the liver-biopsy speci-
mens obtained from the five surviving children 1 to 45 
months after transplantation. The biopsy specimens 
also showed no evidence of rejection. 
Amylopectin deposits were found in all biopsy 
specimens of skin (including arrectores pilorum mus-
cles), jejunum, and skeletal muscle obtained at the 
time of transplantation. Postmortem studies in Pa-
tient 3, who died 36 days after transplantation at 36 
months of age, showed amylopectin in the esophagus, 
bowel, bladder smooth muscle, skeletal muscle, cen-
tral nervous system, peripheral nerves, and heart. In 
this patient, amylopectin occupied about 2 percent of 
the myocardial area (Table 2). 
Myocardial samples were available from three other 
patients (Table 2). Patient I, whose liver was replaced 
when he was 36 months old, had a nearly amylopec-
tin-free mvocardial-biopsy specimen 54 months later. 
His younger brother (Patient 6) had involvement of 13 
percent of the myocardial area three weeks after trans-
plantation (Table 2). A year later, the amount of amy-
lopectin had been reduced to 5.9 percent (Fig. I, Ta-
ble 2). In Patient 7, the mvocardial-biopsv specimen 
obtained one month after liver transplantation showed 
very few deposits in the myocvtes; 10 months later, 
there was no change. 
DISCUSSION 
The absence of amvlopectin deposition in ,he liver 
grafts was expected, but (he freedom from neuromus-
cular or cardiac morbidity associated with extrahepat-
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A B 
c D 
However, there WJ.S little J.mylo-
pectin in myocardial-biopsy speci-
mens obtained a year or more after 
liver transplantation. Particularly 
striking was the decrease in myo-
cardial amylopectin over a period 
of 13 months after liver transplan-
tation in Patient 6, whose older 
brother had minimal heart involve-
ment 54 months after transplanta-
tion. We speculate that the older 
brother may have cleared amylo-
pectin from his extrahepatic tissues 
by the time this first heart biopsy 
was performed. That amylopectin 
disappears slowly is illustrated by 
the cases of our patients and may 
account for unpublished observa-
tions in a 14-month-old Belgian 
child who died of a respiratory in-
fection superimposed on congestive 
heart failure II months "D~fter liver 
transplantation. Amylopectin was 
found post mortem in this child's 
myocardium and in other organs 
(Otte ]B, University of Louvain 
Medical School, Brussels: personal 
communication) . 
Figure 1. Myocardial Biopsy Specimens from Patient 6 (PAS-D, x40S). 
These observations could have 
implications for other enzyme defi-
ciencies that affect multiple organs, 
particularly if cell-to-cell transfer 
of the deficient enzyme can be dem-
onstrated. However, any explana-
tion for extrahepatic amylopectin 
clearance must await a better un-
derstanding of the paradoxical en-
zymologic features of Type IV gly-
cogen storage disease, in which a 
branching-enzyme defect results in 
glycogen with fewer than normal 
branches. 2 Furthermore, the distri-
bution of the normal and abnormal 
branching enzymes may be differ-
ent in various tissues. 21 
Transverse sections (Panel A) and oblique sections (Panel B) of myocardial fibers in a 
biopsy specimen obtained 3% weeks after liver transplantation show abundant amylo-
pectin inclUSIons (red material). Panels C and D show comparable fields from a biopsy 
specimen obtained 14 months after transplantation, in which there IS evidence of a Finally, it is possible that long-
term cyclosporine therapy was an 
ameliorating factor in our patients. 
marked decrease in the number of inclusions. 
ic amylopectin deposits was more noteworthv. No 
neuromuscular complications were seen, and the re-
tarded growth tha't was characteristic of the patients 
belore transplantation was restored to more ne<1.rlv 
normal values in all the survivors. :Viore important, 
none of the surviving patients has had cJrdiac compli-
cations during follow-up periods as long as six vears. 
Because a wide varietv of ,;ardiac and non cardiac tis-
sues collected perioperativelv trom dilferf'11l patient' 
contained cytopiasmiclmvlopectin. ;1 must he 1, 
~umed that ail the patil"nt:; had cardiac ;nvol\"l"lT1t'nl. 
as \vas demonstratt'd in '.he !cJUr Datients "ttldied. 
This drug,22 as well as the new immunosuppressive 
agent .FK 506,23 has hepatotrophic qualities similar to 
those of insulin,z4 includin~ the ability to increase he-
patic glvcogen stores. Both these immunosuppressive 
drul2;s attach to cvtosolic binding sites that are rich in 
the ubiquitous enzyme peptidyl-prolyl isomerase/5,26 
and both cause wide-ranging immunologic and non-
immunologic effects, includin~ alterations in carbohy-
drate, cholesterol, and uric acid metabolism.'3 Thus. it 
is concen'able that the early treatment of patients with 
f\pe IV glycogen storage disease could obviate the 
:1eed lor transplantation. 
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